NASDAQ : AGMB
AgomAb Therapeutics NV — Key statistics
Healthcare · Biotechnology · Belgium
Last price 7.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 368.87M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 368.87M |
| Enterprise Value | 82.29M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 14, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 49.25M |
| Shares Change (YoY) | +3,716.54% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.19% |
| Owned by Institutions (%) | 44.75% |
| Float | 20.99M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.89 |
| P/TBV Ratio | 5.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.88 |
| Quick Ratio | 12.55 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -329.71 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -24.35% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.50M |
| Employee Count | 62 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 10.92 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 29.20 |
| Average Volume (20 Days) | 115,375 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 941,904 |
| Short Previous Month | 1.00M |
| Short % of Shares Out | 2.31% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.88 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -75.34M |
| Pretax Income | -76.15M |
| Net Income | -93.23M |
| EBITDA | -74.90M |
| EBIT | -75.34M |
| Earnings Per Share (EPS) | -$4.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 287.88M |
| Total Debt | 1.30M |
| Net Cash | 286.57M |
| Net Cash Per Share | $5.82 |
| Equity (Book Value) | 303.18M |
| Book Value Per Share | 2.59 |
| Working Capital | 272.38M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -63.53M |
| Capital Expenditures | -4,480 |
| Depreciation & Amortization | 426,328 |
| Net Borrowing | -379,663 |
| Free Cash Flow | -63.53M |
| FCF Per Share | -$1.29 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3,716.54% |
| Shareholder Yield | n/a |
| Earnings Yield | -60.27% |
| FCF Yield | -17.22% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $37.67 |
| Price Target Difference | 402.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |